Abstract
Aims and background: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA 2+-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. Methods and study design: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. Results: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. Conclusions: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.
| Original language | English |
|---|---|
| Pages (from-to) | 32-34 |
| Number of pages | 3 |
| Journal | Tumori |
| Volume | 85 |
| Issue number | 1 |
| Publication status | Published - Jan 1999 |
Fingerprint
Keywords
- E-cadherin
- IEMA method
- Lung cancer
- Tumor marker
ASJC Scopus subject areas
- Cancer Research
Cite this
Serum-soluble E-cadherin fragments in lung cancer. / Cioffi, Michele; Gazzerro, Patrizia; Di Finizio, Bruno; Vietri, Maria Teresa; Di Macchia, Catia; Puca, Giovanni Alfredo; Molinari, Anna Maria.
In: Tumori, Vol. 85, No. 1, 01.1999, p. 32-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum-soluble E-cadherin fragments in lung cancer
AU - Cioffi, Michele
AU - Gazzerro, Patrizia
AU - Di Finizio, Bruno
AU - Vietri, Maria Teresa
AU - Di Macchia, Catia
AU - Puca, Giovanni Alfredo
AU - Molinari, Anna Maria
PY - 1999/1
Y1 - 1999/1
N2 - Aims and background: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA 2+-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. Methods and study design: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. Results: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. Conclusions: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.
AB - Aims and background: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA 2+-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. Methods and study design: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. Results: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. Conclusions: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.
KW - E-cadherin
KW - IEMA method
KW - Lung cancer
KW - Tumor marker
UR - http://www.scopus.com/inward/record.url?scp=0033045449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033045449&partnerID=8YFLogxK
M3 - Article
C2 - 10228494
AN - SCOPUS:0033045449
VL - 85
SP - 32
EP - 34
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 1
ER -